Breakthrough Discovery: Dr. Denis Evseenko’s laboratory at USC is also the co-inventor of Plurocart—a first-in-class cell-based therapy designed to fundamentally change the treatment of degenerative joint disease.

About Plurocart: Plurocart is a pluripotent stem cell-derived cartilage therapy that directly addresses the root causes of joint degeneration. Unlike current treatments that primarily manage symptoms, Plurocart aims to restore functional cartilage, reduce chronic inflammation, and promote tissue repair. By targeting the underlying pathology of joint deterioration, Plurocart represents a true step toward disease-modifying therapy.

Clinical Translation: Building on this foundation, Plurocart is positioned for clinical development with the goal of providing patients a minimally invasive, disease-modifying solution preventing post-traumatic cartilage and eventually, entire joint degeneration. The therapy exemplifies the potential of stem cell-based approaches to redefine standards of care and improve quality of life. The FDA submission for Prurocart clinical trial has been submitted in July 2025. Based on the feedback the Accelerator team is anticipating full IND clearance and the launch of the clinical trial in early 2026.

Impact and Vision: Plurocart has the potential to spare patients from years of pain, reduce reliance on symptomatic medications, and delay or eliminate the need for joint replacement. Beyond OA, its regenerative mechanism opens possibilities for treating a wide spectrum of degenerative and inflammatory musculoskeletal disorders, underscoring the transformative potential of this discovery.

By inventing Plurocart and advancing it toward clinical translation, our team has set a new benchmark in regenerative medicine.